Post-earnings recap
Reported
Mon, May 4, 2026
EPS actual
$-1.26
EPS est.
$-0.85
EPS surprise
-48.06%
1-day move
+8.31%
Axsome Therapeutics reported a larger-than-expected loss per share, which disappointed analysts. Despite this, the stock rose by 8.31%, indicating that investors may be optimistic about future developments or other aspects of the business not reflected in the earnings numbers.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.26 | $-0.76 | -48.06% |
| Revenue | — | $192M | — |
No transcript is on record for the earnings call, so the analysis is based solely on numerical results.
Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders. With a market cap of $11 billion, its work is crucial as it targets unmet medical needs in mental health and neurological conditions.
Last quarter
In Q4-2025, Axsome reported an EPS of -$0.56, which was better than analysts' expectations of -$0.70, resulting in a positive surprise. However, the stock fell 4.88% the next day, indicating market disappointment despite the beat.
EPS beat streak
0Q
EPS beat rate
50%
Avg EPS surprise
-12.53%
Avg 1-day reaction
+2.76%
Analysts expect Axsome to report a loss of $0.76 per share on revenues of $192 million. The market is closely watching how the company manages its costs and sales growth.
Bull case
If Axsome can exceed revenue expectations and improve its EPS, it may signal strong demand for its products and effective cost management, boosting investor confidence.
Bear case
Conversely, if the company fails to meet revenue expectations or reports a wider loss, it could raise concerns about its growth prospects and operational efficiency.
Key metrics to watch
EPS
-$0.76Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
$192MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Axsome's revenue exceed the consensus estimate of $192 million?
Revenue performance is critical for assessing market demand and the company's growth trajectory.
Q2
What specific strategies is Axsome implementing to improve its EPS from the expected -$0.76?
Understanding management's approach to cost control and revenue generation will be key to evaluating future profitability.
—
Est. EPS
$0.25
Est. Rev
$156M
Impl. Move
±16.1%
Why consensus could be wrong
The Street may underestimate Axsome's ability to leverage its pipeline effectively, leading to stronger-than-expected revenue growth.
Supporting evidence
The recent EPS surprise of +20.34% indicates potential for better performance than anticipated.
Options pricing suggests a significant move, indicating that traders expect volatility which could favor a positive outcome.
Key risk
If revenue comes in below $164 million, it could undermine confidence in Axsome's growth strategy.
Pre-commit to what would confirm each case.
This quarter, the focus is on Axsome's ability to generate revenue and improve profitability amidst ongoing operational challenges.
Bull confirmed if
Revenue growth exceeding $192 million with a narrower EPS loss than -$0.76 would confirm the bull case.
Bear confirmed if
A revenue figure below $164 million or an EPS loss worse than -$0.96 would confirm the bear case.
What the market is pricing for the move.
Implied Move
±7.52%
Historical Avg
±4.6%
The options market is pricing in a significant move around the earnings report, suggesting that traders expect volatility based on the results.
Options are pricing ±7.5% while AXSM has averaged ±4.6% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
47.2%
Smart-money positioning from the most recent 13F filings.
Institutional
74.59%
of float
Insider
15.08%
of float
Holders
661
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
3,103,708 sh · $536.8M
5.93%
-20.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Axsome beats expectations, history suggests the stock could rise by about 2.93%, confirming positive market sentiment.
In line / cautious
If results are in line but management's commentary is cautious, the stock may experience a muted reaction as investors reassess growth prospects.
Miss
Should the company miss expectations, history suggests a potential decline of around 0.42%, reflecting investor disappointment.
The lines on the call that would change the story.
Vanguard Portfolio Management LLC
1,983,514 sh · $343.1M
3.79%
-3.6%
Vanguard Capital Management LLC
1,965,086 sh · $339.9M
3.75%
1.4%
Invesco Ltd.
1,671,684 sh · $289.2M
3.19%
28.8%
FMR, LLC
1,539,163 sh · $266.2M
2.94%
-1.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.